

- 85 -

CLAIMS

1. A compound that is [((1R,2S,5R)-2-isopropyl-5-methyl-cyclohexanecarbonyl)-amino]-acetic acid isopropyl ester, or a pharmaceutically acceptable salt, hydrate,  
5 or solvate thereof, for use in a method of treatment of chronic cough.
2. Use of a compound that is [((1R,2S,5R)-2-isopropyl-5-methyl-cyclohexanecarbonyl)-amino]-acetic acid isopropyl ester, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, in the manufacture of a medicament  
10 for the treatment of chronic cough.
3. A method of treatment of chronic cough comprising administering to a patient in need of treatment a therapeutically effective amount of a compound that is [((1R,2S,5R)-2-isopropyl-5-methyl-cyclohexanecarbonyl)-amino]-acetic acid  
15 isopropyl ester, or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
4. A kit comprising (a) a compound that is [((1R,2S,5R)-2-isopropyl-5-methyl-cyclohexanecarbonyl)-amino]-acetic acid isopropyl ester, or a pharmaceutically acceptable salt, hydrate, or solvate thereof; and (b) instructions for its use for the  
20 treatment of chronic cough.
5. A compound according to claim 1, use according to claim 2, a method according to claim 3, or a kit according to claim 4, wherein:  
the chronic cough is explained chronic cough.  
25
6. A compound according to claim 1, use according to claim 2, a method according to claim 3, or a kit according to claim 4, wherein:  
the chronic cough is chronic cough as a symptom of, associated with, or  
caused by: a diagnosed condition.  
30
7. A compound according to claim 1, use according to claim 2, a method according to claim 3, or a kit according to claim 4, wherein:  
the chronic cough is chronic cough as a symptom of, associated with, or  
caused by: a diagnosed cough-related condition.  
35
8. A compound according to claim 1, use according to claim 2, a method according to claim 3, or a kit according to claim 4, wherein:  
the chronic cough is chronic cough as a symptom of, associated with, or  
caused by: asthma, eosinophilic bronchitis, post-nasal drip syndrome (PNDS),  
40 gastro-oesophageal reflux disease (GORD), bronchiectasis chronic obstructive pulmonary disease (COPD), or idiopathic pulmonary fibrosis (IPF).

9. A compound according to claim 1, use according to claim 2, a method according to claim 3, or a kit according to claim 4, wherein:  
the chronic cough is idiopathic chronic cough (ICC).
- 5
10. A compound according to claim 1, use according to claim 2, a method according to claim 3, or a kit according to claim 4, wherein:  
the chronic cough is refractory chronic cough (RCC).
- 10
11. A compound according to claim 1, use according to claim 2, a method according to claim 3, or a kit according to claim 4, wherein:  
the chronic cough is refractory chronic cough (RCC) that persists after assessment and treatment of a cough-related condition.
- 15
12. A compound according to claim 1, use according to claim 2, a method according to claim 3, or a kit according to claim 4, wherein:  
the chronic cough is refractory chronic cough (RCC) that persists after assessment and treatment of: asthma, eosinophilic bronchitis, post-nasal drip syndrome (PNDS), gastro-oesophageal reflux disease (GORD), bronchiectasis chronic obstructive pulmonary disease (COPD), or idiopathic pulmonary fibrosis (IPF).
- 20
13. A compound according to any one of claims 1 and 5 to 12, use according to any one of claims 2 and 5 to 12, a method according to any one of claims 3 and 5 to 12, or a kit according to any one of claims 4 to 12, wherein:  
the chronic cough is a symptom of, associated with, or caused by: allotussia.
- 25
14. A compound according to any one of claims 1 and 5 to 12, use according to any one of claims 2 and 5 to 12, a method according to any one of claims 3 and 5 to 12, or a kit according to any one of claims 4 to 12, wherein:  
the chronic cough is a symptom of, associated with, or caused by: hypertussia.
- 30
- 35

- 87 -

15. A compound according to any one of claims 1 and 5 to 12,  
use according to any one of claims 2 and 5 to 12,  
a method according to any one of claims 3 and 5 to 12, or  
a kit according to any one of claims 4 to 12, wherein:  
5 the chronic cough is a symptom of, associated with, or caused by: cough  
hypersensitivity syndrome (CHS).
16. A compound according to any one of claims 1 and 5 to 12,  
use according to any one of claims 2 and 5 to 12,  
10 a method according to any one of claims 3 and 5 to 12, or  
a kit according to any one of claims 4 to 12, wherein:  
the chronic cough is a symptom of, associated with, or caused by: cough  
hypersensitivity reflex (CHR).
17. A compound according to any one of claims 1 and 5 to 12,  
use according to any one of claims 2 and 5 to 12,  
a method according to any one of claims 3 and 5 to 12, or  
a kit according to any one of claims 4 to 12, wherein:  
15 the chronic cough is a symptom of, associated with, or caused by:  
laryngeal paraesthesia.  
20
18. A compound according to any one of claims 1 and 5 to 12,  
use according to any one of claims 2 and 5 to 12,  
a method according to any one of claims 3 and 5 to 12, or  
25 a kit according to any one of claims 4 to 12, wherein:  
the chronic cough is a symptom of, associated with, or caused by:  
laryngeal hypersensitivity syndrome (LHS).
19. A compound according to any one of claims 1 and 5 to 12,  
use according to any one of claims 2 and 5 to 12,  
30 a method according to any one of claims 3 and 5 to 12, or  
a kit according to any one of claims 4 to 12, wherein:  
the chronic cough is sensory neuropathic cough.
20. A compound according to any one of claims 1 and 5 to 12,  
use according to any one of claims 2 and 5 to 12,  
35 a method according to any one of claims 3 and 5 to 12, or  
a kit according to any one of claims 4 to 12, wherein:  
the chronic cough is a symptom of, associated with, or caused by:  
40 peripheral sensitization; central sensitization (cough centre); and/or cortical and/or  
subcortical maladaptive plasticity.

21. A compound according to any one of claims 1 and 5 to 12,  
use according to any one of claims 2 and 5 to 12,  
a method according to any one of claims 3 and 5 to 12, or  
5 a kit according to any one of claims 4 to 12, wherein:  
the chronic cough is a symptom of, associated with, or caused by: vagal  
neuropathy.
22. A compound according to any one of claims 1 and 5 to 12,  
10 use according to any one of claims 2 and 5 to 12,  
a method according to any one of claims 3 and 5 to 12, or  
a kit according to any one of claims 4 to 12, wherein:  
the chronic cough is a symptom of, associated with, or caused by: airway  
inflammation.
23. A compound according to any one of claims 1 and 5 to 12,  
15 use according to any one of claims 2 and 5 to 12,  
a method according to any one of claims 3 and 5 to 12, or  
a kit according to any one of claims 4 to 12, wherein:  
20 the chronic cough is a symptom of, associated with, or caused by:  
neurogenic inflammation and/or neuroinflammation.
24. A compound according to any one of claims 1 and 5 to 23,  
25 use according to any one of claims 2 and 5 to 23,  
a method according to any one of claims 3 and 5 to 23, or  
a kit according to any one of claims 4 to 23, wherein:  
the treatment is to reduce cough frequency;  
the treatment is to reduce hourly cough frequency;  
the treatment is to reduce median hourly cough frequency;  
30 the treatment is to reduce mean hourly cough frequency;  
the treatment is to reduce awake hourly cough frequency;  
the treatment is to reduce awake median hourly cough frequency;  
the treatment is to reduce awake mean hourly cough frequency;  
the treatment is to reduce asleep hourly cough frequency;  
35 the treatment is to reduce asleep median hourly cough frequency;  
the treatment is to reduce asleep mean hourly cough frequency;  
the treatment is to reduce cough severity;  
the treatment is to reduce urge-to-cough; and/or  
the treatment is to reduce throat irritation.
- 40

25. A compound according to any one of claims 1 and 5 to 24,  
use according to any one of claims 2 and 5 to 24,  
a method according to any one of claims 3 and 5 to 24, or  
a kit according to any one of claims 4 to 24, wherein:
- 5           the treatment is by topical oral administration of the compound;  
            the treatment is by topical oromucosal administration of the compound;  
            the treatment is by topical buccal administration of the compound;  
            the treatment is by topical sublingual administration of the compound;  
            the treatment is by topical intranasal administration of the compound; or  
10          the treatment is by topical transmucosal administration of the compound.
26. A compound according to any one of claims 1 and 5 to 25,  
use according to any one of claims 2 and 5 to 25,  
a method according to any one of claims 3 and 5 to 25, or  
15          a kit according to any one of claims 4 to 25, wherein:
- the treatment is with a dose in the range of from about 1 µg to  
            about 5 mg of the compound per kilogram body weight of the subject per day;  
            the treatment is with a dose in the range of from about 5 µg to  
            about 2 mg of the compound per kilogram body weight of the subject per day;  
20          the treatment is with a dose in the range of from about 15 µg to  
            about 0.7 mg of the compound per kilogram body weight of the subject per day;  
            the treatment is with a dose in the range of from about 30 µg to  
            about 0.4 mg of the compound per kilogram body weight of the subject per day; or  
            the treatment is with a dose in the range of from about 70 µg to  
25          about 0.3 mg of the compound per kilogram body weight of the subject per day.
27. A compound according to any one of claims 1 and 5 to 25,  
use according to any one of claims 2 and 5 to 25,  
a method according to any one of claims 3 and 5 to 25, or  
30          a kit according to any one of claims 4 to 25, wherein:
- the treatment is with a dose in the range of from about 0.07 mg to  
            about 350 mg of the compound per day;  
            the treatment is with a dose in the range of from about 0.35 mg to  
            about 140 mg of the compound per day;  
35          the treatment is with a dose in the range of from about 1 mg to  
            about 50 mg of the compound per day;  
            the treatment is with a dose in the range of from about 2 mg to  
            about 30 mg of the compound per day; or  
            the treatment is with a dose in the range of from about 5 mg to  
40          about 20 mg of the compound per day.

- 90 -

28. A compound according to any one of claims 1 and 5 to 27,  
use according to any one of claims 2 and 5 to 27,  
a method according to any one of claims 3 and 5 to 27, or  
a kit according to any one of claims 4 to 27, wherein:
- 5                   the treatment is by a treatment regimen of 1 to 5 administrations daily;  
                  the treatment is by a treatment regimen of 1 to 4 administrations daily;  
                  the treatment is by a treatment regimen of 2 to 5 administrations daily;  
                  the treatment is by a treatment regimen of 2 to 4 administrations daily;  
                  the treatment is by a treatment regimen of 2 administrations daily;
- 10                  the treatment is by a treatment regimen of 3 administrations daily; or  
                  the treatment is by a treatment regimen of 4 administrations daily.
29. A compound according to any one of claims 1 and 5 to 28,  
use according to any one of claims 2 and 5 to 28,
- 15                  a method according to any one of claims 3 and 5 to 28, or  
                  a kit according to any one of claims 4 to 28, wherein:  
                  the treatment is by a *pro re nata* (PRN) treatment regimen.
30. A compound according to any one of claims 1 and 5 to 29,  
use according to any one of claims 2 and 5 to 29,  
a method according to any one of claims 3 and 5 to 29, or  
a kit according to any one of claims 4 to 29, wherein:
- 20                   the compound is formulated as a tablet;  
                  the compound is formulated as an orally disintegrating tablet (ODT);
- 25                   the compound is formulated as a spray;  
                  the compound is formulated as a mist; or  
                  the compound is formulated as an aerosol.